A unique collection of 590 tyrosine kinase inhibitors for high throughput screening and high content screening for drug discovery in tyrosine kinase related diseases;Bioactivity and safety confirmed by pre-clinical research and clinical trials, and some of them are approved by FDA;Targets include c-Kit, c-Met, EGFR, FGFR, SRC, JAK, SYK, Btk, Bcr-Abl, etc;Detailed compound information with structure, target, activity, IC50 value, and biological activity description;Structurally diverse, medicinally active, and cell permeable;NMR and HPLC validated to ensure high purity and quality;